Osteomet

Osteomet

zoledronic acid

Manufacturer:

UNILAB, Inc

Distributor:

UNILAB, Inc
Concise Prescribing Info
Contents
Zoledronic acid
Indications/Uses
Hypercalcemia of malignancy (HCM), multiple myeloma, bone metastases from solid tumors (including prostate cancer, breast cancer, lung cancer, renal cell carcinoma, other solid tumors) in combination w/ standard antineoplastic therapy to prevent or delay potential complications from bone lesions.
Dosage/Direction for Use
IV infusion Hypercalcemia of malignancy [albumin-corrected serum Ca >12 mg/dL (3 mmol/L)] 4 mg as single dose over not <15 min following standard rehydration procedures. Bone metastases of solid tumors & osteolytic lesions of multiple myeloma (for patient w/ CrCl >60 mL/min) 4 mg as single dose over not <15 min every 3-4 wk. Patients w/ CrCl 50-60 mL/min 3.5 mg given every 3-4 wk. 40-49 mL/min 3.3 mg given every 3-4 wk. 30-39 mL/min 3 mg given every 3-4 wk.
Contraindications
Hypersensitivity. Pregnancy & lactation.
Special Precautions
Monitor serum levels of Ca, phosphate & Mg after initiating therapy. Evaluate serum creatinine conc prior to therapy. Hydration & electrolyte monitoring. Renal impairment; musculoskeletal pain; osteonecrosis of the jaw; atypical fractures of the femur; asthma. Discontinue use if ocular disturbances occur. May impair ability to drive or operate machinery. Hepatic impairment. Childn 1-17 yr. Elderly.
Adverse Reactions
Fever & flu-like syndrome, fatigue, chills, rigors, malaise & flushing, progression of cancer, weakness, rigors; CV, CNS, GI, hemic & lymphatic system effects; infections, inj site reactions, laboratory abnormalities,musculoskeletal/connective tissue & bone disorders; ocular, renal & urinary, resp, skin & SC tissue disorders.
Drug Interactions
Increased risk of hypocalcemia w/ loop diuretics. Possible additive effect in lowering serum Ca conc for prolonged periods w/ aminoglycosides. Increased risk of renal impairment w/ nephrotoxic drug (eg, other antineoplastic agents, ASA, NSAIDs) or drugs that significantly impact renal function (eg diuretics, ACE inhibitors). Increased risk of renal insufficiency w/ thalidomide (especially in patients w/ multiple myeloma).
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Presentation/Packing
Form
Osteomet concentrated soln for infusion 4 mg/5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in